MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.86
-0.12
-1.34%
After Hours: 8.72 -0.14 -1.58% 17:20 10/23 EDT
OPEN
9.10
PREV CLOSE
8.98
HIGH
9.10
LOW
8.76
VOLUME
21.82K
TURNOVER
--
52 WEEK HIGH
30.40
52 WEEK LOW
4.510
MARKET CAP
31.78M
P/E (TTM)
-0.0266
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / October 8, 2020 / Achieve Life Sciences, Inc.
ACCESSWIRE · 10/08 10:30
Achieve Life Sciences Announces Start oO Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline For Smoking Cessation
SEATTLE and VANCOUVER, B.C., Oct. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and
Benzinga · 10/07 10:43
Achieve Life Sciences names John Bencich as the new CEO
Achieve Life Sciences (ACHV) promotes John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve's Chief Financial and Operating Officer since 2017.Rick Stewart, company's current Chairman and CEO, will continue
Seekingalpha · 09/30 13:05
ACHV: Achieve Updates and RAUORA
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT On September 18, 2020, two presentations related to Achieve Life Sciences (NASDAQ:ACHV) were given at the Society for Research on Nicotine and Tobacco European (SRNT-E) Annual Meeting. The first presentation addressed Achieve’s
Zacks Small Cap Research · 09/21 10:17
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced presentation of final results from the RAUORA trial, led by Dr. Natalie Walker,
PR Newswire · 09/18 14:30
Positive data from cytisinicline comparative study in smoking cessation lifts Achieve Life
Achieve Life Sciences ([[ACHV]] +18.0%) announced presentation of final results from the RAUORA trial evaluating the effectiveness and safety of cytisinicline compared to Pfizer's varenicline as a smoking cessation aid in
Seekingalpha · 09/18 14:01
Achieve Life Sciences' cytisinicline beats Pfizer's varenicline in smoking cessation study
Achieve Life Sciences ([[ACHV]] +18.0%) announced presentation of final results from the RAUORA trial evaluating the effectiveness and safety of cytisinicline compared to Pfizer's varenicline as a smoking cessation aid in
Seekingalpha · 09/18 14:01
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACHV stock price target is 43.75 with a high estimate of 100.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 1.11M
% Owned: 30.98%
Shares Outstanding: 3.59M
TypeInstitutionsShares
Increased
3
1.52K
New
15
304.16K
Decreased
1
10.69K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Executive Director
Richard Stewart
President
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Director
Scott Cormack
Independent Director
Donald Joseph
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
Independent Director
H. Stewart Parker
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.